Status:
UNKNOWN
Carbapenem Antibiotic Therapy for VIM Carbapenemase-Producing Enterobacteriaceae Infections
Lead Sponsor:
University Hospital, Strasbourg, France
Conditions:
Carbapenemase-Producing Enterobacteriaceae
Eligibility:
All Genders
18+ years
Brief Summary
Carbapenemase-producing Enterobacteriaceae (CPE) infections are emerging infections that pose a therapeutic challenge. These infections mainly occur in patients with prolonged hospitalization and repe...
Detailed Description
The circulation of multi-antibiotic-resistant bacterial strains is significant at the Strasbourg University Hospital and the investigators wish to report their local experience in the use of carbapene...
Eligibility Criteria
Inclusion
- Adult patient (≥18)
- Treated at the HUS for a VIM-producing enterobacteria infection between 01/01/2011 and 11/30/2022
- Subjects who have not expressed their opposition to the reuse of their data for scientific research purposes.
Exclusion
- Patient having expressed his opposition to the retrospective reuse of his data for scientific research purposes.
Key Trial Info
Start Date :
November 21 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2023
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT06185153
Start Date
November 21 2022
End Date
December 1 2023
Last Update
December 29 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Service des Maladies Infectieuses et Tropicales - CHU de Strasbourg - France
Strasbourg, France, 67091